Testing tumors with next-generation sequencing in patients with ovarian cancer can provide teams insight into targetable mutations that may affect treatment decisions, although this approach is not the current standard of care for all patients, an expert said.
In an
Researchers examined risks for Black and white women with endometriosis and fibroids to understand how common medical interventions for those conditions modified the outcomes
SEATTLE, WA — May 4, 2023 — A new Fred Hutchinson Cancer Center study in the
Clearity’s Perspective: Ask your health care team if they have a social worker, financial navigator, patient navigator, or nurse navigator who can help you manage the financial impacts of cancer. See Clearity’s Information and Support Resources for national organizations that … Read more
by Jennifer Southall
Whole-exome sequencing identified carriers of predisposition genes for hereditary breast and ovarian cancer or Lynch syndrome who, under current guidelines, would not have qualified for genetic testing, according to study results.
The findings, presented at American Association … Read more
by Matthew Shinkle
One of every four patients with a gynecologic oncology office visit had inadequate levels of cancer health literacy, according to data presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
Researchers found racial and ethnic … Read more
Ovarian cancer outcomes are less positive for Black and African American persons compared to other communities, but the reasons why are not entirely clear. Anne Mette Buhl, PhD, Director of Science and Clinical Trials, from The Clearity Foundation, recently contributed … Read more
by Caroline Seymour
Treatment with the folate receptor α–directed antibody-drug conjugate luveltamab tazevibulin led to a 37.5% overall response rate in Frα-selected patients with advanced ovarian cancer, defined by a tumor proportion score above 25%.
Treatment with the folate receptor
by Chris Ryan
Treatment with mirvetuximab soravtansine elicited a statistically significant benefit vs investigator’s choice of chemotherapy for the OV28 abdominal/gastrointestinal symptom subscale in patients with folate receptor alpha–positive, advanced ovarian cancer.
Treatment with mirvetuximab soravtansine elicited a statistically significant
— A response to “practice-changing data” in the first- and second-line setting
by Mike Bassett
by Kristi Rosa
Maintenance treatment with niraparib produced a sustained and durable progression-free survival benefit in patients with primary advanced ovarian cancer who responded to first-line platinum-based chemotherapy, spanning biomarker subgroups.
Maintenance treatment with niraparib (Zejula) produced a sustained and
by Jordyn Sava
In an interview with Targeted Oncology during the EMSO Annual Congress, David O’Malley, MD, discussed the phase 1 study of ubamatamab in ovarian cancer.
Ubamatamab, a novel MUC16 antibody, demonstrated evidence of durable responses in patients with … Read more
by Mike Bassett
— Results from SOLO-1 and PAOLA-1 show “clinically meaningful” long-term results with olaparib
PARIS — Olaparib (Lynparza) maintenance therapy appears to offer a long-term overall survival (OS) benefit for women with ovarian cancer, according to two phase … Read more
CCR scientists have identified dozens of naturally occurring receptors that direct immune cells to tumors with mutations in p53, the most commonly mutated gene in human cancers. The research team, led by Steven Rosenberg, M.D., Ph.D., Chief of the … Read more
by Vicki Moore, PhD
Researchers found that 18% of patients with advanced ovarian cancer remained disease-free for at least 10 years after receiving chemotherapy and were likely cured. The team detailed their findings in Gynecologic Oncology.
To determine what … Read more
by Leslie Cantu
A combination of up to five drugs normally used … Read more
On June 4, 2022 the Clearity community of supporters, donors, volunteers, staff and participants gathered at the La Jolla home of founders Dr. Laura Shawver and Tracy Macuga to honor Scientific Director, Dr. Deborah Zajchowski and celebrate her retirement.
Dr. … Read more
by Lindsey Fischer
A real-world analysis showed that the proportion of women with ovarian cancer who required dose modifications or treatment discontinuations while receiving PARP inhibitors differed significantly between olaparib, niraparib, and rucaparib.
Patients with ovarian cancer treated with FDA-approved
by Caroline Hopkins
CHICAGO – AstraZeneca’s investigational WEE1 inhibitor adavosertib showed potential in biomarker-selected advanced ovarian cancer populations in two studies presented during the American Society of Clinical Oncology’s annual meeting Saturday.
The drug, which AstraZeneca licensed from Merck in … Read more
by Amanda Ferguson
Daniel Durocher’s lab designed a new drug with CRISPR-Cas9 gene-editing technology that blocks an enzyme essential for the survival of certain cancer cells (photo courtesy of Sinai Health
Scientists at Sinai Health and the University of Toronto … Read more
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
